Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 01, 2023 | June 05, 2023 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | August 17, 2017 | August 21, 2017 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 02, 2019 | January 04, 2019 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 06, 2024 | July 15, 2024 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,564 |
Reported balance
After 2023-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 4,216 · Balance 26,564 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 4,216 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.92 · Expires 2033-06-01 | Direct | 12,649 |
Reported balance
After 2023-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-01 · Grant · Acquired 12,649 · Balance 12,649 F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 4,216 unvested RSUs.
F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Editas Medicine, Inc.
Report date August 17, 2017 · Filed August 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,171 |
Reported balance
After 2017-08-17 transaction · row 1
1 source rowRow 1 · 2017-08-17 · Other · Acquired 1,686 · Balance 3,171 F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,361,400 shares and 340,349 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 57,022 shares and 11 shares it received from Flagship IV and Flagship IV-Rx, respectively. Mr. Cole, a member of Flagship IV LLC, received 1,686 shares through such distribution. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,361,400 shares and 340,349 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 57,022 shares and 11 shares it received from Flagship IV and Flagship IV-Rx, respectively. Mr. Cole, a member of Flagship IV LLC, received 1,686 shares through such distribution.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Quanterix Corp
Report date January 02, 2019 · Filed January 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,540 |
Reported balance
After 2019-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 2,270 · Balance 4,540 F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2019 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2: Includes 2,270 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.24 · Expires 2029-01-02 | Direct | 7,900 |
Reported balance
After 2019-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-02 · Grant · Acquired 7,900 · Balance 7,900 F3: Represents non-qualified stock option to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2019 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F2: Includes 2,270 restricted stock units.
F3: Represents non-qualified stock option to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy.
Sana Biotechnology, Inc.
Report date June 06, 2024 · Filed July 15, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.36 · Expires 2034-06-05 | Direct | 65,000 |
Reported balance
After 2024-06-06 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 65,000 · Balance 65,000 F1: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F2: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.
F2: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 20:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 28,000 | $4.08 Strike: $4.08 | $114,240.00 |
DisclosureSEC source: 0001486373-26-000005 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:25 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 25,000 | $4.79 Strike: $4.79 | $119,750.00 |
DisclosureSEC source: 0001562180-25-004893 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-16 Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $5.52 Strike: $5.52 | $88,320.00 |
DisclosureSEC source: 0001562180-24-005358 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-25 Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:21 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 54,278 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-004840 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,278 Underlying: Common Stock · 54,278 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jul 15, 2024 20:11 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-005718 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-05 F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $5.00 Strike: $9.92 | $3,413.91 |
DisclosureSEC source: 0001415889-23-012136 · form4-08112023_040826.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2032-05-25 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $6.64 Strike: $8.28 | $4,537.78 |
DisclosureSEC source: 0001415889-23-012136 · form4-08112023_040826.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2033-05-18 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 00:14 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005479 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-20 Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:33 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005027 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 12,649 | $0.00 Strike: $30.92 | $0.00 |
DisclosureSEC source: 0001714899-23-000093 · wk-form4_1686002460.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,649 Underlying: Common Stock · 12,649 shares Expires 2033-06-01 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-23-000093 · wk-form4_1686002460.xml · nonDerivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,564 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 4,216 unvested RSUs. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:20 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-23-008492 · form4-05222023_040501.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2033-05-18 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024 Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 01:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001562180-22-005318 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-20 Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:35 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001562180-22-004942 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,959 | $0.00 Strike: $24.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000095 · wf-form4_165456052861515.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,959 Underlying: Common Stock · 17,959 shares Expires 2032-06-02 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000095 · wf-form4_165456052861515.xml · nonDerivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,348 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 11,035 shares received in prior distributions-in-kind made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · balance_after: Includes 5,986 unvested restricted stock units. Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:00 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-22-005826 · form4-05272022_050508.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023 Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 20:52 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 12,530 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-21-004932 · primarydocument.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,530 Underlying: Common Stock · 12,530 shares Expires 2031-07-12 F1 · derivative.exercise_date: The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 11:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $9.97 Strike: $9.97 | $88,613.36 |
DisclosureSEC source: 0001415889-21-003236 · form4-06282021_070600.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:31 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 6,222 | $0.00 Strike: $63.76 | $0.00 |
DisclosureSEC source: 0001209191-21-038374 · doc4.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Underlying: Common Stock · 6,222 shares Expires 2031-06-02 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:31 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038374 · doc4.xml · nonDerivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,327 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:51 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038035 · doc4.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:51 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038035 · doc4.xml · nonDerivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005072 · doc4.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-02-02 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. Read SEC document |
| February 03, 2021 Filed Feb 18, 2021 23:58 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 23,591 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007191 · doc4a.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,591 Underlying: Common Stock · 23,591 shares Expires 2031-02-02 F1 · shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F2 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034764 · doc4.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Underlying: Common Stock · 3,253 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F3 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 15,183 | $0.00 Strike: $28.82 | $0.00 |
DisclosureSEC source: 0001209191-20-034764 · doc4.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 Underlying: Common Stock · 15,183 shares Expires 2030-06-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 30, 2019 Filed May 31, 2019 22:28 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,245 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-19-033722 · doc4.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,245 Underlying: Common Stock · 27,245 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:02 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $18.24 | $0.00 |
DisclosureSEC source: 0001562180-19-000190 · primarydocument.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2029-01-02 F3 · shares: Represents non-qualified stock option to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:02 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-000190 · primarydocument.xml · nonDerivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,540 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2019 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| August 07, 2018 Filed Aug 10, 2018 00:12 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $14.80 | $0.00 |
DisclosureSEC source: 0001104659-18-051029 · a4.xml · derivative · entry 2 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2028-08-07 Read SEC document |
| August 07, 2018 Filed Aug 10, 2018 00:12 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-051029 · a4.xml · nonDerivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2018. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Represents 2,270 restricted stock units. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,830 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001209191-18-038154 · doc4.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,830 Underlying: Common Stock · 27,830 shares Expires 2028-06-12 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 22:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 47,165 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-17-064804 · doc4.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 Underlying: Common Stock · 47,165 shares Expires 2027-12-06 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 20:17 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | OtherCommon Stock | 1,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000637 · edgar.xml · nonDerivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,171 F1 · kind: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,361,400 shares and 340,349 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 57,022 shares and 11 shares it received from Flagship IV and Flagship IV-Rx, respectively. Mr. Cole, a member of Flagship IV LLC, received 1,686 shares through such distribution. F1 · price: On August 17, 2017, Flagship Ventures Fund IV, L.P. ("Flagship IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship IV LLC"), pro rata and without consideration, 1,361,400 shares and 340,349 shares, respectively, of the Issuer's common stock. Flagship IV LLC, in turn, distributed to its members, pro rata and without consideration, the 57,022 shares and 11 shares it received from Flagship IV and Flagship IV-Rx, respectively. Mr. Cole, a member of Flagship IV LLC, received 1,686 shares through such distribution. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $15.63 | $0.00 |
DisclosureSEC source: 0001179110-17-009264 · edgar.xml · derivative · entry 1 Cole Douglas G. · CIK 0001486373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2027-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.